Thymosin Alpha-1
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic 28-amino-acid peptide marketed as an immune modulator for immune support, viral infections, and cancer. Human evidence is narrow: mixed efficacy findings in chronic hepatitis B and inconclusive sepsis benefit, but longevity and immune-boosting claims are weak. It must not be used in immunosuppressed or transplant patients, and may worsen autoimmune disease. Approved abroad as thymalfasin but not FDA-approved or eligible for US compounding; unregulated products sold online are of uncertain quality.
Read Full recordStudied uses & evidence
Studied uses(7)
Chronic hepatitis B treatment (sustained virological response)
HighMultiple human RCTs and meta-analyses show a sustained, delayed virological response; approved in 35+ countries.
Enhanced hepatitis C treatment in combination with interferon
LowHuman trials raised end-of-treatment response, but durable benefit over interferon alone was not significant.
Reduced mortality in sepsis (meta-analysis evidence)
MediumA 2025 pooled analysis found lower mortality, but the largest, best-designed trials were negative.
Evidence limits
- Evidence Level
- Level 1-2 — Strong
Thymosin Alpha-1 has among the strongest clinical evidence bases of any peptide therapeutic outside of FDA-approved products. Hepatitis B results are mixed. Some trials and pooled analyses report delayed virological responses, while the 97-patient placebo-controlled phase III trial did not confirm efficacy. The sepsis evidence includes 11 RCTs with a cumulative 1,927 patients, though the largest single trial (TESTS, n=1106) was negative. The cancer immunotherapy data includes Phase II trials with FDA orphan drug designations. The COVID-19 evidence is mixed, with some studies showing immune restoration but no definitive mortality benefit. Safety data is exceptionally strong: over 11,000 treated individuals with no clinically significant adverse reactions attributable to Ta1. Animal toxicology studies showed no adverse reactions at up to 800x the clinical dose. The overall clinical picture supports Ta1 as a well-tolerated immune modulator with mixed evidence in hepatitis B and promising but inconclusive evidence in sepsis and cancer. The hepatitis indication is now largely historical given the advent of direct-acting antivirals.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Organ transplant recipients on immunosuppressants
HighImmune stimulation may counteract immunosuppressive therapy and trigger organ rejection.
Active autoimmune flare
ModerateWhile sometimes used for autoimmune modulation, acute flares may worsen with immune stimulation.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site discomfort/erythema (most common)
HighContraindicated in deliberately immunosuppressed patients (e.g., transplant)
HighImmune stimulation could theoretically aggravate autoimmune disease
TheoreticalRare allergic reactions
LowRare transient muscle atrophy, polyarthralgia with hand edema, rash
LowUncertain US regulatory status; compounded/research-grade quality
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.